Columbia Faces Renewed Scrutiny as Officials Demand AG Probe $1 Billion Hadden Scandal

Allegations of a whitewashed inquiry into Columbia University’s OBGYN scandal lay bare persistent institutional blind spots—testing trust in elite medical establishments and oversight in New York.

On a chilly March morning, New Yorkers passing Columbia University’s wrought-iron gates witnessed a tableau that has become too familiar in recent years: somber activists, survivors and city officials denouncing what they called an institutional whitewash of sexual assault. The occasion was the university’s much-anticipated report on Dr. Robert Hadden, its former OBGYN, who was convicted of sexually abusing hundreds of female patients for over two decades. Rather than offering closure, the report has fuelled fresh outrage.

Columbia’s internal review lands amidst a public furor still simmering over Hadden’s crimes. Between 1987 and 2012, he preyed on women within the hallowed halls of Columbia’s medical center and NewYork-Presbyterian Hospital. Although the university ultimately dismissed him after his predations became publicly known, the aftershocks continue. Over the past decade, Columbia has paid more than $1bn to settle 1,000-plus sexual assault claims tied to Hadden’s tenure—a staggering sum that hints at the scale and depth of institutional failure.

Assembly Member Grace Lee, standing with survivors and faculty, dismissed the university’s report as a “box-checking exercise,” accusing it of simply reciting public information rather than pursuing genuine accountability. Most damningly, the report failed to probe events after Hadden’s firing in 2012, skirting uncomfortable questions: How did so many warnings go unheeded for so long? Who, among staff and administrators, facilitated or looked away from abuses? The omissions have only compounded doubts about Columbia’s willingness to grapple with its past.

For New York City, always anxious about the probity of its leading institutions, the affair portends more than headlines and legal settlements. Columbia’s medical faculty is both pillar and symbol—if the city’s top hospital cannot manage internal oversight, what does it bode for patient safety elsewhere? Columbia’s campus, draped in the banners of progress, has now become a focal point for discussing the city’s fraught relationship with institutional transparency and responsibility.

The current dispute is not merely about paperwork or public relations. Survivors and their advocates argue that Columbia’s apparent reticence to investigate itself fully puts patients at continued risk. Despite decade-old reforms and payouts, Assembly Member Lee and others reckon there are likely staffers complicit in the cover-up still employed at the hospital. Apprehensions about whether anything has truly changed weigh on students, residents and practitioners, who depend on these institutions’ reputations for safety and decency.

Financially, the bottom line is already sobering. Payouts topping $1bn have not, apparently, bought accountability or trust—merely, some might say, the right to keep operating. The indirect costs are harder to tally: loss of faith among prospective patients, chilling effects on talented faculty recruitment, and an emboldened skepticism towards elite medicine. Hospitals elsewhere in New York, while quietly relieved the scandal did not originate within their own wards, take note. The city’s legal and insurance environment can only become more aggressive in response.

Politically, the call for state Attorney General Letitia James to step in signals a waning of deference to the self-regulation of storied institutions. Trust in the regulatory judgements of universities, once gospel, now crumbles amid revelations that, when the foxes guard the henhouse, the hens rarely fare well. Activists sense momentum: the city and state stand poised to set stiffer expectations for how public wrongs are investigated by private actors. That could mark a turn towards greater government scrutiny, as officials seek to demonstrate vigilance where deference has failed.

Institutional reckoning, national lessons

While Hadden’s case is uniquely horrific in its scope, such patterns are hardly unfamiliar across America’s elite universities. The University of Southern California, Michigan State, and others have all made headlines in recent years for systemic failures to stamp out abuse. Yet the Columbia saga holds particular salience for advocates who argue that even the “best” institutions are vulnerable when incentives to avoid scandal outweigh imperatives to protect the vulnerable.

Globally, the reverberations will not be lost on other top-ranked academic medical centres, whether in London, Paris or Toronto. The revelations from New York contrast starkly with European approaches, where independent ombudsmen and regulatory bodies occasionally wield sharper teeth than risk-averse university boards. For America, this may be an object lesson in the perils of self-inquiry; for New York, an urgent signal that the old, clubby reliance on internal reviews has reached its sell-by date.

From a policy perspective, the numbers here are sobering. $1bn spent suggests not so much a willingness to make amends as the magnitude of the initial dereliction—few institutions, however storied, can weather such outlays without material consequence. While the city’s economy remains robust, public patience for university exceptionalism is anything but buoyant.

It is tempting to attribute such failures to a handful of bad actors. Yet the Columbia report—both in what it omits and what it concedes—portends a deeper cultural hesitancy to confront organizational shortcomings. The city’s leadership, as well as its academic heavyweights, must reckon with the costs of opacity and the mismatch between rhetoric and reform.

In the wry vernacular of New York life, some will view Columbia’s latest measure as an expensive insurance policy—one that does little to rectify what has already been lost. Cynicism, as so often in this city, is more than justified. But the question now, for lawmakers, students and patients alike, is whether meaningful oversight can be compelled from outside, or whether even graver failures must occur before the lessons are truly learned.

For Columbia and its peers, the moment is both cautionary and clarifying. Reform, if it is to mean more than PowerPoint slides and PR gymnastics, will require relinquishing a cherished instinct for handling matters “in the family”. Whether the city’s—and country’s—finest hospitals will finally divest themselves of this habit remains a far more consequential question than any in-house report dares ask. ■